The Zhitong Finance App learned that on May 8, the CDE official website showed that Novartis Pharmaceuticals (NVS.US)'s new Class 1 drug PIT565 was clinically approved for use in rheumatoid arthritis. PIT565 is a first-of-its-kind CD3/CD19/CD2 triple antibody. Compared with the CD3 double antibody, CD2 co-stimulation through PIT565 can overcome T cell depletion and increase the depth and duration of the patient's response.

Zhitongcaijing · 05/09 06:25
The Zhitong Finance App learned that on May 8, the CDE official website showed that Novartis Pharmaceuticals (NVS.US)'s new Class 1 drug PIT565 was clinically approved for use in rheumatoid arthritis. PIT565 is a first-of-its-kind CD3/CD19/CD2 triple antibody. Compared with the CD3 double antibody, CD2 co-stimulation through PIT565 can overcome T cell depletion and increase the depth and duration of the patient's response.